Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial

Cynthia S Rand, Andrew Bilderback, Kathleen Schiller, Jonathan M. Edelman, Carolyn M. Hustad, Robert S. Zeiger

Research output: Contribution to journalArticle

Abstract

Background: Nonadherence with asthma therapy is common and may contribute to poor clinical outcomes. Objective: To examine the effect of dosing frequency and mode of delivery of therapy on adherence and clinical outcomes. Methods: We examined adherence in patients with mild persistent asthma (15-85 years) enrolled in a randomized study of montelukast (10 mg once daily) or fluticasone (88 μg, 2 puffs twice daily) during a 12-week double-blind treatment period (DB), followed by a 36-week open-label trial (OL). Adherence was monitored using eDEM for montelukast/placebo and MDILog devices for fluticasone/placebo. Results: Participants used at least 1 puff of inhaled therapy on 83.3% DB/76.8% OL of days and at least 1 dose of oral therapy on 77.5%/71.4% of days (P <.0001). Subjects used inhaled therapy less than prescribed on 49.5%/57.5% of days, compared with 22.5%/28.6% of days for oral therapy (P <.0001). In the DB, a dose-response relationship was observed with fluticasone and asthma rescue-free days (P = .02) and FEV1 percent predicted (P <.01) only for patients with FEV1 ≤ 86%. In the OL period, a dose-response relationship was observed with fluticasone and FEV1 percent predicted (P <.001). Conclusion: Whereas subjects were more likely to use inhaled fluticasone/placebo at least once a day, subjects were more likely to take once-daily oral montelukast/placebo as prescribed. Clinical outcomes were inconsistently associated with adherence levels. Clinical implications: Patients were less likely to be fully adherent with twice-daily therapy than with once-daily therapy, but most still achieved adequate asthma control.

Original languageEnglish (US)
Pages (from-to)916-923
Number of pages8
JournalThe Journal of Allergy and Clinical Immunology
Volume119
Issue number4
DOIs
StatePublished - Apr 2007

Fingerprint

montelukast
Adrenal Cortex Hormones
Asthma
Clinical Trials
Placebos
Therapeutics
Fluticasone

Keywords

  • Adherence
  • clinical trial
  • compliance
  • dose-response
  • fluticasone
  • inhaled corticosteroids
  • leukotriene receptor antagonist
  • mild persistent asthma
  • montelukast

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Adherence with montelukast or fluticasone in a long-term clinical trial : Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial. / Rand, Cynthia S; Bilderback, Andrew; Schiller, Kathleen; Edelman, Jonathan M.; Hustad, Carolyn M.; Zeiger, Robert S.

In: The Journal of Allergy and Clinical Immunology, Vol. 119, No. 4, 04.2007, p. 916-923.

Research output: Contribution to journalArticle

Rand, Cynthia S ; Bilderback, Andrew ; Schiller, Kathleen ; Edelman, Jonathan M. ; Hustad, Carolyn M. ; Zeiger, Robert S. / Adherence with montelukast or fluticasone in a long-term clinical trial : Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial. In: The Journal of Allergy and Clinical Immunology. 2007 ; Vol. 119, No. 4. pp. 916-923.
@article{c27d235e9db5418695c68dd92cb8c9a7,
title = "Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial",
abstract = "Background: Nonadherence with asthma therapy is common and may contribute to poor clinical outcomes. Objective: To examine the effect of dosing frequency and mode of delivery of therapy on adherence and clinical outcomes. Methods: We examined adherence in patients with mild persistent asthma (15-85 years) enrolled in a randomized study of montelukast (10 mg once daily) or fluticasone (88 μg, 2 puffs twice daily) during a 12-week double-blind treatment period (DB), followed by a 36-week open-label trial (OL). Adherence was monitored using eDEM for montelukast/placebo and MDILog devices for fluticasone/placebo. Results: Participants used at least 1 puff of inhaled therapy on 83.3{\%} DB/76.8{\%} OL of days and at least 1 dose of oral therapy on 77.5{\%}/71.4{\%} of days (P <.0001). Subjects used inhaled therapy less than prescribed on 49.5{\%}/57.5{\%} of days, compared with 22.5{\%}/28.6{\%} of days for oral therapy (P <.0001). In the DB, a dose-response relationship was observed with fluticasone and asthma rescue-free days (P = .02) and FEV1 percent predicted (P <.01) only for patients with FEV1 ≤ 86{\%}. In the OL period, a dose-response relationship was observed with fluticasone and FEV1 percent predicted (P <.001). Conclusion: Whereas subjects were more likely to use inhaled fluticasone/placebo at least once a day, subjects were more likely to take once-daily oral montelukast/placebo as prescribed. Clinical outcomes were inconsistently associated with adherence levels. Clinical implications: Patients were less likely to be fully adherent with twice-daily therapy than with once-daily therapy, but most still achieved adequate asthma control.",
keywords = "Adherence, clinical trial, compliance, dose-response, fluticasone, inhaled corticosteroids, leukotriene receptor antagonist, mild persistent asthma, montelukast",
author = "Rand, {Cynthia S} and Andrew Bilderback and Kathleen Schiller and Edelman, {Jonathan M.} and Hustad, {Carolyn M.} and Zeiger, {Robert S.}",
year = "2007",
month = "4",
doi = "10.1016/j.jaci.2006.12.664",
language = "English (US)",
volume = "119",
pages = "916--923",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Adherence with montelukast or fluticasone in a long-term clinical trial

T2 - Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial

AU - Rand, Cynthia S

AU - Bilderback, Andrew

AU - Schiller, Kathleen

AU - Edelman, Jonathan M.

AU - Hustad, Carolyn M.

AU - Zeiger, Robert S.

PY - 2007/4

Y1 - 2007/4

N2 - Background: Nonadherence with asthma therapy is common and may contribute to poor clinical outcomes. Objective: To examine the effect of dosing frequency and mode of delivery of therapy on adherence and clinical outcomes. Methods: We examined adherence in patients with mild persistent asthma (15-85 years) enrolled in a randomized study of montelukast (10 mg once daily) or fluticasone (88 μg, 2 puffs twice daily) during a 12-week double-blind treatment period (DB), followed by a 36-week open-label trial (OL). Adherence was monitored using eDEM for montelukast/placebo and MDILog devices for fluticasone/placebo. Results: Participants used at least 1 puff of inhaled therapy on 83.3% DB/76.8% OL of days and at least 1 dose of oral therapy on 77.5%/71.4% of days (P <.0001). Subjects used inhaled therapy less than prescribed on 49.5%/57.5% of days, compared with 22.5%/28.6% of days for oral therapy (P <.0001). In the DB, a dose-response relationship was observed with fluticasone and asthma rescue-free days (P = .02) and FEV1 percent predicted (P <.01) only for patients with FEV1 ≤ 86%. In the OL period, a dose-response relationship was observed with fluticasone and FEV1 percent predicted (P <.001). Conclusion: Whereas subjects were more likely to use inhaled fluticasone/placebo at least once a day, subjects were more likely to take once-daily oral montelukast/placebo as prescribed. Clinical outcomes were inconsistently associated with adherence levels. Clinical implications: Patients were less likely to be fully adherent with twice-daily therapy than with once-daily therapy, but most still achieved adequate asthma control.

AB - Background: Nonadherence with asthma therapy is common and may contribute to poor clinical outcomes. Objective: To examine the effect of dosing frequency and mode of delivery of therapy on adherence and clinical outcomes. Methods: We examined adherence in patients with mild persistent asthma (15-85 years) enrolled in a randomized study of montelukast (10 mg once daily) or fluticasone (88 μg, 2 puffs twice daily) during a 12-week double-blind treatment period (DB), followed by a 36-week open-label trial (OL). Adherence was monitored using eDEM for montelukast/placebo and MDILog devices for fluticasone/placebo. Results: Participants used at least 1 puff of inhaled therapy on 83.3% DB/76.8% OL of days and at least 1 dose of oral therapy on 77.5%/71.4% of days (P <.0001). Subjects used inhaled therapy less than prescribed on 49.5%/57.5% of days, compared with 22.5%/28.6% of days for oral therapy (P <.0001). In the DB, a dose-response relationship was observed with fluticasone and asthma rescue-free days (P = .02) and FEV1 percent predicted (P <.01) only for patients with FEV1 ≤ 86%. In the OL period, a dose-response relationship was observed with fluticasone and FEV1 percent predicted (P <.001). Conclusion: Whereas subjects were more likely to use inhaled fluticasone/placebo at least once a day, subjects were more likely to take once-daily oral montelukast/placebo as prescribed. Clinical outcomes were inconsistently associated with adherence levels. Clinical implications: Patients were less likely to be fully adherent with twice-daily therapy than with once-daily therapy, but most still achieved adequate asthma control.

KW - Adherence

KW - clinical trial

KW - compliance

KW - dose-response

KW - fluticasone

KW - inhaled corticosteroids

KW - leukotriene receptor antagonist

KW - mild persistent asthma

KW - montelukast

UR - http://www.scopus.com/inward/record.url?scp=34047248519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047248519&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2006.12.664

DO - 10.1016/j.jaci.2006.12.664

M3 - Article

C2 - 17349681

AN - SCOPUS:34047248519

VL - 119

SP - 916

EP - 923

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -